The Berlin Heart EXCOR Pediatric (EXCOR) ventricular assist device (VAD) was introduced in North America nearly 2 decades ago. The EXCOR was approved under Humanitarian Device Exemption status in 2011 and received post-market approval (PMA) in 2017 from Food and Drug Administration. Since the initial approval, the field of pediatric mechanical circulatory support has changed, specifically with regard to available devices, anticoagulation strategies, and the types of patients supported. This report summarizes the outcomes of patients supported with EXCOR from the Advanced Cardiac Therapies Improving Outcomes Network (ACTION) registry. These data were part of the PMA surveillance study (PSS) required by the Food and Drug Administration.
ACTION is a learning collaborative of over 40 pediatric heart failure programs worldwide, which collects data for all VAD implantations as one of its initiatives. All patients in North America with EXCOR implants reported to ACTION from 2018 to 2020 (n = 72) who had met an outcome were included in the EXCOR PSS group. This was compared with a historical, previously reported Berlin Heart EXCOR study group (Berlin Heart study [BHS] group, n = 320, 2007‒2014).
Patients in the PSS group were younger, were smaller in weight/body surface area, were more likely to have congenital heart disease, and were less likely to receive a bi-VAD than those in the BHS group. Patients in the PSS group were less likely to be in Interagency Registry for Mechanically Assisted Circulatory Support Profile 1 and were supported for a longer duration. The primary anticoagulation therapy for 92% of patients in the PSS group was bivalirudin. Success, defined as being transplanted, being weaned for recovery, or being alive on a device at 180 days after implantation, was 86% in the PSS group compared with 76% in the BHS group. Incidence of stroke was reduced by 44% and the frequency of pump exchange by 40% in the PSS group compared with those in the BHS group. Similarly, all other adverse events, including major bleeding, were reduced in the PSS group.
The PSS data, collected through ACTION, highlight the improvement in outcomes for patients supported with EXCOR compared with the outcomes in a historical cohort. These findings may be the result of changes in patient care practices over time and collaborative learning.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to The Journal of Heart and Lung Transplantation
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Third Annual Pediatric Interagency Registry for Mechanical Circulatory Support (Pedimacs) report: preimplant characteristics and outcomes.Ann Thorac Surg. 2019; 107: 993-1004
- The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: twenty-first pediatric heart transplantation report-2018; focus theme: multiorgan transplantation.J Hear Lung Transplant. 2018; 37: 1184-1195
- The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: twenty-second pediatric heart transplantation report - 2019; focus theme: donor and recipient size match.J Hear Lung Transplant. 2019; 38: 1028-1041
- Berlin Heart EXCOR Pediatric ventricular assist device Investigational Device Exemption study: study design and rationale.Am Heart J. 2011; 162 (425-35.e6)
- The European Registry for Patients with Mechanical Circulatory Support (EUROMACS): first EUROMACS Paediatric (Paedi-EUROMACS) report.Eur J Cardiothorac Surg. 2018; 54: 800-808
- Postapproval outcomes: the Berlin heart EXCOR pediatric in North America.ASAIO J. 2017; 63: 193-197
- The creation of a Pediatric Health Care Learning Network: the ACTION quality improvement collaborative.ASAIO J. 2020; 66: 441-446
- Utilization and outcomes of children treated with direct thrombin inhibitors on paracorporeal ventricular assist device support.ASAIO J. 2020; 66: 939-945
- Marked practice variation in antithrombotic care with the Berlin heart EXCOR pediatric ventricular assist device.ASAIO J. 2019; 65: 731-737
- Bivalirudin experience in a heterogeneous ventricular assist device Population.ASAIO J. 2020; 66: 677-682
- Prospective trial of a pediatric ventricular assist device.N Engl J Med. 2012; 367: 532-541
- Berlin heart EXCOR pediatric ventricular assist device for bridge to heart transplantation in US children.Circulation. 2013; 127: 1702-1711
- The impact of pre-implant illness severity on the outcomes of pediatric patients undergoing durable ventricular assist device.J Hear Lung Transplant. 2020; 39: 666-674
- Is implantation of a left ventricular assist device in patients With critical or impending cardiogenic shock an absolute contraindication? Looking back at our past experience trying to identify contraindicative risk factors.Artif Organs. 2015; 39: 998-1004
- Berlin Heart EXCOR use in patients with congenital heart disease.J Heart Lung Transplant. 2017; 36: 1209-1216
- Mechanical cardiac support in children with congenital heart disease with intention to bridge to heart transplantation†.Eur J Cardiothorac Surg. 2014; 46: 656-662
- Outcomes of children with congenital heart disease implanted with ventricular assist devices: an analysis of the Pediatric Interagency Registry for Mechanical Circulatory Support (Pedimacs) [published correction appears in J Heart Lung Transplant 2020;39:1512-4].J Hear Lung Transplant. 2019; 38: 420-430
- Delineating survival outcomes in children <10 kg bridged to transplant or recovery with the Berlin Heart EXCOR ventricular assist device.JACC Hear Fail. 2015; 3: 70-77
- ABCs of stroke prevention: improving stroke outcomes in children supported with a ventricular assist device in a Quality Improvement Network.Circ Cardiovasc Qual Outcomes. 2020; 13e006663
- Exemplar pediatric collaborative improvement networks: achieving results.Pediatrics. 2013; 131: S196-S203
Published online: January 19, 2021
© 2021 International Society for Heart and Lung Transplantation. All rights reserved.